ACRS - CIK 0001557746
The table below shows Aclaris Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.96M | $24.57M | $39.88M | $45.28M | $27.35M | $22.06M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | $318.00K | $298.00K | $484.00K | $623.00K | $772.00K |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $96.32M |
| $125.95M |
| $128.86M |
| $231.55M |
| $205.03M |
| $57.49M |
| Property, plant & equipment | $761.00K | $1.01M | $1.62M | $1.10M | $1.33M | $1.65M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $160.46M | $220.33M | $197.41M | $254.60M | $251.21M | $70.78M |
| Accounts payable | $13.16M | $4.69M | $8.88M | $10.35M | $9.98M | $5.25M |
| Total current liabilities | $28.64M | $31.60M | $30.95M | $21.94M | $22.93M | $14.87M |
| Long-term debt | - | - | - | - | $10.65M | $10.65M |
| Total liabilities | $57.38M | $64.77M | $40.23M | $56.98M | $53.87M | $33.13M |
| Retained earnings | -$967.78M | -$902.86M | -$770.80M | -$682.32M | -$595.41M | -$504.54M |
| Total equity | $103.08M | $155.55M | $157.18M | $197.62M | $197.34M | $37.65M |